Clinical Drug Investigation

, Volume 24, Issue 8, pp 479–486 | Cite as

Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease and Established Azathioprine Therapy

  • L. P. L. GilissenEmail author
  • L. J. J. Derijks
  • L. P. Bos
  • P. J. Bus
  • P. M. Hooymans
  • L. G. J. B. Engels
Original Research Article


Background and objective

Azathioprine is widely used in the treatment of corticosteroid-dependent and refractory inflammatory bowel disease (IBD). The efficacy of this treatment is based on the production of 6-thioguanine nucleotides, but extremely elevated levels may cause bone marrow suppression. Other azathioprine metabolites, 6-methylmercaptopurine ribonucleotides, are associated with hepatotoxicity. Therapeutic drug monitoring (TDM) may be of help in optimising azathioprine treatment, but data on TDM in established azathioprine therapy are lacking. We therefore measured metabolite levels in a small cohort of patients established on azathioprine therapy.

Patients and methods

6-Thioguanine (6-TGN) and 6-methylmercaptopurine (6-MMP) levels in erythrocytes were measured in 15 IBD outpatients established on azathioprine therapy for at least 3 months at baseline and 1, 4 and 8 weeks after inclusion (mean duration of treatment 28 months; range 7–67 months). Disease activity was evaluated by the Crohn’s Disease Activity Index (Crohn’s disease) or Truelove-Witts (ulcerative colitis) scores. Metabolite levels were measured by modified high-performance liquid chromatography assay (HPLC). Primary outcome measures were 6-TGN and 6-MMP metabolite levels and 95% confidence intervals (CIs). Secondary outcomes were correlations between metabolite levels, drug dose, disease activity and laboratory parameters and compliance.


One patient had active disease during the study period. Eleven of 15 patients (73%) completed the 8-week study period. Dropout reasons were noncompliance in three patients (20%) and intolerance in one patient (7%).

Primary outcomes

At baseline mean 6-TGN levels were 158 (95% CI 113, 203) pmo1/8·108 RBC (red blood cells), steadily increasing over the 8-week study period, but not significantly. Two patients had zero levels. Another two had significantly increasing levels also suggesting noncompliance. Mean 6-MMP levels showed almost a similar pattern. At baseline, levels were 2213 (95% CI 722, 3704) mo1/8·108 RBC.

Secondary outcomes

A correlation was found between all RBC 6-MMP levels and azathioprine dose (mg/kg bodyweight) [r = 0.43, p = 0.001] and also between the 6-MMP/6-TGN ratio and azathioprine dose (mg/kg) [r = 0.36, p = 0.010). There was no correlation between RBC 6-TGN or 6-MMP levels and haematological parameters or disease activity scores. No hepatic, pancreatic or myelotoxicity occurred.

Thirteen of 15 patients (87%) had baseline steady-state 6-TGN levels below the therapeutic threshold of 235 pmol/8·108 RBC. Forty percent (6/15) of our patients were noncompliant; TDM revealed this noncompliance in four of the six patients (27% of all patients).


Our small study demonstrates that TDM may provide insight into individual pharmacokinetics. However, TDM does not seem to be useful in patients with IBD established on azathioprine therapy and without disease activity, although it may be helpful in cases of worsening IBD activity to elucidate noncompliance or inefficient treatment.


Inflammatory Bowel Disease Therapeutic Drug Monitoring Inflammatory Bowel Disease Patient Thiopurine Azathioprine Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study received no external funding. The authors have no potential conflicts of interest directly relevant to the contents of this article.


  1. 1.
    Lancaster DL, Lennard L, Rowland K, et al. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations. Br J Haematol 1998; 102: 439–43PubMedCrossRefGoogle Scholar
  2. 2.
    Bergan S, Rugstad HE, Bentdal O, et al. Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. Ther Drug Monit 1994; 16: 13–20PubMedCrossRefGoogle Scholar
  3. 3.
    Suarez-Almazor M, Spooner C, Belseck E. Azathioprine for rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD001461PubMedGoogle Scholar
  4. 4.
    Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med 1995; 123(2): 132–42PubMedGoogle Scholar
  5. 5.
    Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am J Gastroenterol 1996; 91(3): 423–33PubMedGoogle Scholar
  6. 6.
    Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111(8): 641–9PubMedGoogle Scholar
  7. 7.
    Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990; 85(6): 717–22PubMedGoogle Scholar
  8. 8.
    Baert F, Rutgeerts P. 6-Thioguanine: a naked bullet? (or how pharmacogenomics can make old drugs brand new). Inflamm Bowel Dis 2001; 7(3): 190–1CrossRefGoogle Scholar
  9. 9.
    Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43(4): 329–39PubMedCrossRefGoogle Scholar
  10. 10.
    Hanauer SB, Meyers SM. Management of Crohn’s disease in adults. Am J Gastroenterol 1997; 92(4): 559–66PubMedGoogle Scholar
  11. 11.
    Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995; 37: 674–8PubMedCrossRefGoogle Scholar
  12. 12.
    Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn’s disease with 6-mercaptopurine: a long-term randomised double-blind study. N Engl J Med 1980; 302: 981–7PubMedCrossRefGoogle Scholar
  13. 13.
    Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001; 48: 591–2PubMedCrossRefGoogle Scholar
  14. 14.
    Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705–13PubMedCrossRefGoogle Scholar
  15. 15.
    Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48(5): 642–6PubMedCrossRefGoogle Scholar
  16. 16.
    Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn’s disease: correlation with efficacy and toxicity. Gut 1996; 39: 401–6PubMedCrossRefGoogle Scholar
  17. 17.
    Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665–70PubMedCrossRefGoogle Scholar
  18. 18.
    Gupta P, Gokhale R, Kirschner B. 6-Mercaptopurine (6MP) metabolite levels in children with IBD. J Pediatr Gastroenterol Nutr 2001; 33(4): 450–4PubMedCrossRefGoogle Scholar
  19. 19.
    Cuffari C, Hunt S, Bayless T. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000; 14: 1009–14PubMedCrossRefGoogle Scholar
  20. 20.
    Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn’s disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001; 7(3): 181–9PubMedCrossRefGoogle Scholar
  21. 21.
    Derijks LJJ, De Jong DJ, Gilissen LPL, et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003; 15(1): 63–7PubMedCrossRefGoogle Scholar
  22. 22.
    Dubinsky MC, Feldman EJ, Abreu MT, et al. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003; 98(5): 1058–63PubMedCrossRefGoogle Scholar
  23. 23.
    Tiede I, Fritz G, Strand S, et al. CD28-dependent Racl activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111(8): 133–45Google Scholar
  24. 24.
    Lennard L. TPMT in the treatment of Crohn’s disease with azathioprine. Gut 2002; 51: 143–6PubMedCrossRefGoogle Scholar
  25. 25.
    Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 188: 1025–30CrossRefGoogle Scholar
  26. 26.
    Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115(4): 813–21PubMedCrossRefGoogle Scholar
  27. 27.
    Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34(8): 1081–5PubMedCrossRefGoogle Scholar
  28. 28.
    Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125: 298–303PubMedCrossRefGoogle Scholar
  29. 29.
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955; 4947: 1041–8CrossRefGoogle Scholar
  30. 30.
    Lennard L, Singleton HJ. High performance liquid Chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-mercaptopurine metabolites in a single sample. J Chromatogr 1992; 583(1): 83–90PubMedCrossRefGoogle Scholar
  31. 31.
    Derijks LJJ, Gilissen LPL, Engels, LGJ, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004; 26: 311–8PubMedCrossRefGoogle Scholar
  32. 32.
    Pettersson B, Aimer S, Albertioni F, et al. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate [abstract]. Ther Drug Monit 2002; 24: 351–8PubMedCrossRefGoogle Scholar
  33. 33.
    Reuther LO, Vainer B, Sonne J, et al. Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders: the impact of TPMT genotyping in predicting toxicity. Eur J Clin Pharmacol 2003; 59(11): 797–801PubMedCrossRefGoogle Scholar
  34. 34.
    Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 118: 395–400CrossRefGoogle Scholar
  35. 35.
    Curvers WL, Derijks LJJ, Stokkers P, et al. No predictive value of TPMT genotyping for leukopenia or hepatotoxicity during azathioprine therapy in inflammatory bowel disease [abstract]. Eur J Gastroenterol Hepatol 2003; 15(12): A29Google Scholar
  36. 36.
    Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of 6-mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance. Br J Cancer 1995; 72: 1004–6PubMedCrossRefGoogle Scholar
  37. 37.
    Webster S, Sanders DS, Lennard L, et al. Azathioprine metabolites in inflammatory bowel disease and incidence of noncompliance [abstract]. Gut 2002; 50 Suppl. II: A71Google Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • L. P. L. Gilissen
    • 1
    Email author
  • L. J. J. Derijks
    • 2
  • L. P. Bos
    • 3
  • P. J. Bus
    • 4
  • P. M. Hooymans
    • 5
  • L. G. J. B. Engels
    • 3
  1. 1.Department of Internal Medicine and GastroenterologyAcademic Hospital Maastricht (azM)MaastrichtThe Netherlands
  2. 2.Department of Clinical PharmacyMaxima Medical CentreVeldhovenThe Netherlands
  3. 3.Department of GastroenterologyMaasland Hospital SittardSittardThe Netherlands
  4. 4.Department of GastroenterologySt Laurentius Hospital RoermondRoermondThe Netherlands
  5. 5.Department of Clinical PharmacyMaasland Hospital SittardSittardThe Netherlands

Personalised recommendations